Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NeuCyte, Inc.
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, research and development partnerships and commercial collaborations. This edition covers industry pacts that were signed in September and October 2019.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Therapeutic Drug Monitoring
- Gene Therapy, Cell Therapy
Drug Discovery Tools